TRIUMPH-1 Dysesthesia Signal Mechanism Discussion: 12.5% at 12 mg Tied to Glucagon-Receptor Activation, Dose-Dependent, Mild and Resolving in TRIUMPH-4 Follow-On
The TRIUMPH-1 dysesthesia signal (skin tingling, paresthesia-like sensations) that BMO Capital flagged Thursday merits a mechanistic look. The signal appeared in 12.5% of participants on retatrutide 12 mg in TRIUMPH-1, but was NOT reported in the Phase 2 retatrutide program. TRIUMPH-4 (December 2025 readout) recorded dysesthesia in approximately 20.9% of participants on the highest dose — most cases mild and resolving during ongoing treatment. The mechanistic explanation is tied to retatrutide's glucagon-receptor activation: glucagon signaling drives small-fiber sensory neuropathy patterns through downstream effects on c-AMP-mediated nociceptor sensitization. The pattern is dose-dependent (4 mg essentially no signal, 9 mg modest, 12 mg the peak). The clinical question is whether dysesthesia stays mild and reversible at commercial scale or whether a small fraction of patients develop persistent or more severe sensory disturbances. The signal is the differentiator from tirzepatide (no glucagon arm) and semaglutide (no glucagon, no GIP).